Just the latest article detailing Big Pharma's move to invest more in research and development capability in China -- not only to cut costs but to acquire a foot hold in what is expected to become the world's largest pharma market in as little as 15 years -- fueled by such factors as 100's of billions in investment in infrastructure by the Chinese goverment, the rise of the middle class and an expected explosion in the numbers of diabetics (thank you Western diet).
Companies that have made significant investments in R&D facilities in China include: Novartis ($1 B), AstraZeneca ($100 M), Novo Nordisk ($100 M), and GSK ($40 M). These companies are far from alone in their commitments to China-based R&D - many others, including Genzyme, Sanofi, Johnson & Johnson, Merck-Serono and Boehringer-Ingelheim, have also established (or plan to establish) R&D bases in mainland China, often at the expense of their Western facilities. Many see the East as integral to any long-term business plan.
As Patrick Keohane, head of R&D, Asia Pacific and Japan at Astrazeneca, puts it: “Asia should now be at the centre of any significant company’s clinical development strategy.”
Posted by Bruce Lehr Sep 15th 2011.